Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis
| Autor: | Anibal Méndez‑Clemente, Alejandro Bravo‑Cuellar, Salvador González‑Ochoa, Maria Santiago‑Mercado, Luis Palafox‑Mariscal, Luis Jave‑Suárez, Fabiola Solorzano‑Ibarra, Maria Villaseñor‑García, Pablo Ortiz‑Lazareno, Georgina Hernández‑Flores |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
STAT3 Transcription Factor Vascular Endothelial Growth Factor A Cancer Research Interleukin-6 Prostate Prostatic Neoplasms General Medicine Antibodies Monoclonal Humanized Cadherins Receptors Interleukin-6 Cyclic S-Oxides Oncology Cell Movement Cell Line Tumor Humans Vimentin Cell Proliferation |
| Zdroj: | Oncology reports. 48(2) |
| ISSN: | 1791-2431 |
| Popis: | Prostate cancer (PCa) is a key public health problem worldwide; at diagnosis, a high percentage of patients exhibit tumor cell invasion of adjacent tissue. STAT‑3, IL‑6 receptor (R) and IL‑6 serum levels are associated with enhanced PCa migratory, invasive, clonogenic and metastatic ability. Inhibiting the STAT‑3 pathway at different levels (cytokines, receptors, and kinases) exhibits relative success in cancer. The present study investigated the effect of Stattic (Stt) + Tocilizumab (Tcz) on proliferative, clonogenic, migratory and invasive ability of human metastatic PCa (assessed by colony formation, wound healing and migration assay). RWPE‑1 (epithelial prostate immortalized cells), 22Rv1 (Tumor cells), LNCaP (Metastatic cells) and DU‑145 (metastatic, castration‑resistant prostate cells) cells were used |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|